GUTS vs. ATRC, MDXG, AORT, CATX, SILK, ATRI, KIDS, EMBC, FNA, and PLSE
Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), Paragon 28 (FNA), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
AtriCure presently has a consensus price target of $49.78, indicating a potential upside of 120.84%. Fractyl Health has a consensus price target of $22.00, indicating a potential upside of 226.41%. Given AtriCure's higher probable upside, analysts plainly believe Fractyl Health is more favorable than AtriCure.
AtriCure has higher revenue and earnings than Fractyl Health.
In the previous week, AtriCure had 2 more articles in the media than Fractyl Health. MarketBeat recorded 8 mentions for AtriCure and 6 mentions for Fractyl Health. Fractyl Health's average media sentiment score of 1.36 beat AtriCure's score of 0.66 indicating that AtriCure is being referred to more favorably in the media.
AtriCure received 544 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
Fractyl Health has a net margin of 0.00% compared to Fractyl Health's net margin of -8.98%. AtriCure's return on equity of 0.00% beat Fractyl Health's return on equity.
99.1% of AtriCure shares are owned by institutional investors. 3.2% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
AtriCure beats Fractyl Health on 8 of the 14 factors compared between the two stocks.
Get Fractyl Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fractyl Health Competitors List
Related Companies and Tools
